Talaris Therapeutics Stock Price, News & Analysis (NASDAQ:TALS) $18.97 -0.03 (-0.16%) (As of 12/5/2023 ET) Add Compare Share Share Today's Range$18.59▼$19.2650-Day Range$2.59▼$19.5052-Week Range$0.89▼$27.95Volume76,969 shsAverage Volume386,531 shsMarket Capitalization$811.23 millionP/E RatioN/ADividend YieldN/APrice Target$7.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media About Talaris Therapeutics Stock (NASDAQ:TALS)Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR001 for the patients with a severe form of scleroderma. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Wellesley, Massachusetts.Read More TALS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TALS Stock News HeadlinesNovember 1, 2023 | msn.comTalaris Therapeutics (TALS) Price Target Increased by 562.50% to 135.15October 19, 2023 | msn.comTalaris Therapeutics goes ex-dividend tomorrowDecember 6, 2023 | Edge On The Street (Ad)Americans Now Favor Gold Over Stocks as an Investment VehicleAmericans now consider gold a better long-term investment than stocks for the first time since 2013. But physical gold requires storage and insurance, and gold mining stocks come with significant risks. Fortunately, investors have found a little-known way to benefit from gold that avoids many of these challenges. October 18, 2023 | finanznachrichten.deTalaris Therapeutics, Inc.: Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline BioOctober 17, 2023 | msn.comTalaris shareholders approve merger, 1-for-10 reverse stock splitOctober 17, 2023 | finance.yahoo.comTalaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline BioOctober 6, 2023 | marketwatch.comShares of Talaris Therapeutics Climb 5.2% on Special Dividend Tied to MergerOctober 6, 2023 | finance.yahoo.comTalaris Therapeutics Declares Special Dividend In Connection with Proposed Merger with Tourmaline BioDecember 6, 2023 | DTI Trader (Ad)New CBOE “special perk” helps traders target income every weekendYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. October 4, 2023 | finance.yahoo.comNew York Blood Center Enterprises Acquires Commercial-Scale Cell & Gene Therapy Development and Manufacturing Facilities from Talaris TherapeuticsSeptember 12, 2023 | finance.yahoo.comWe're Keeping An Eye On Talaris Therapeutics' (NASDAQ:TALS) Cash Burn RateAugust 15, 2023 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AEL, DEN, TALS, QUOTAugust 14, 2023 | finance.yahoo.comImmunoFree Inc. has Acquired Talaris Therapeutics, Inc.'s Tolerance BusinessAugust 8, 2023 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NEX, TALS, QUOT, SURFJuly 28, 2023 | benzinga.comMoore Kuehn Encourages RETA, TALS, INPX, and DEN Investors to Contact Law FirmJuly 27, 2023 | markets.businessinsider.comSHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Talaris Therapeutics, Inc. (TALS)July 18, 2023 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NETI, QUOT, TALS, CFMSJuly 18, 2023 | msn.comTalaris Therapeutics: Cashing Out Ahead Of Tourmaline MergerJuly 6, 2023 | msn.comTalaris Therapeutics (TALS) Price Target Increased by 66.67% to 12.75June 27, 2023 | markets.businessinsider.comIMPORTANT ALERT: Halper Sadeh LLC Investigates TALS, DICE, NEX, NETIJune 26, 2023 | businesswire.comTALARIS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Talaris Therapeutics, Inc. - TALSJune 23, 2023 | benzinga.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Talaris Therapeutics, Inc. MergerJune 23, 2023 | bizjournals.comTalaris Therapeutics announces merger after layoffsJune 22, 2023 | bizjournals.comNY biotech to go public by merging with Boston firm that laid off 95% of staffJune 22, 2023 | msn.comTalaris jumps 29% on merger with Tourmaline Bio in all-stock dealJune 22, 2023 | markets.businessinsider.comIMPORTANT ALERT: Halper Sadeh LLC Investigates TALS, SURF, NEX, CIRJune 22, 2023 | finanznachrichten.deTalaris Therapeutics, Inc.: Talaris Therapeutics and Tourmaline Bio Announce Merger AgreementSee More Headlines Receive TALS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Talaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/12/2021Ex-Dividend for 10/20 Dividend10/20/2023Dividend Payable10/20/2023Today12/06/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TALS CUSIPN/A CIK1827506 Webtalaristx.com Phone502-398-9250FaxN/AEmployees84Year FoundedN/APrice Target and Rating Average Stock Price Target$7.50 High Stock Price Target$12.00 Low Stock Price Target$3.00 Potential Upside/Downside-60.5%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-73,890,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-39.93% Return on Assets-37.37% Debt Debt-to-Equity RatioN/A Current Ratio15.41 Quick Ratio15.41 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.33 per share Price / Book4.38Miscellaneous Outstanding Shares42,764,000Free Float35,708,000Market Cap$811.23 million OptionableNot Optionable Beta2.18 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMs. Mary Kay Fenton (Age 59)Interim CEO, Pres, CFO & Treasurer Comp: $598.98kDr. Suzanne T. Ildstad M.D. (Age 70)Founder, Member of Scientific Advisory Board, Sr. Scientific Advisor & Director Comp: $318.3kMs. Suzanne TollerudVP of Corp. Devel.Key CompetitorsValnevaNASDAQ:VALNPrime MedicineNYSE:PRMEREGENXBIONASDAQ:RGNXAmbrx BiopharmaNYSE:AMAMExscientiaNASDAQ:EXAIView All CompetitorsInsiders & InstitutionsWalleye Capital LLCSold 42,130 shares on 11/21/2023Ownership: 0.614%RA Capital Management L.P.Bought 70,063 shares on 11/15/2023Ownership: 5.620%Affinity Asset Advisors LLCBought 200,000 shares on 11/15/2023Ownership: 0.935%Qube Research & Technologies LtdSold 24,192 shares on 11/14/2023Ownership: 0.024%Barclays PLCBought 10,647 shares on 11/7/2023Ownership: 0.041%View All Insider TransactionsView All Institutional Transactions TALS Stock Analysis - Frequently Asked Questions Should I buy or sell Talaris Therapeutics stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Talaris Therapeutics in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" TALS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TALS, but not buy additional shares or sell existing shares. View TALS analyst ratings or view top-rated stocks. What is Talaris Therapeutics' stock price target for 2024? 2 brokerages have issued 12-month price objectives for Talaris Therapeutics' shares. Their TALS share price targets range from $3.00 to $12.00. On average, they predict the company's share price to reach $7.50 in the next twelve months. This suggests that the stock has a possible downside of 60.5%. View analysts price targets for TALS or view top-rated stocks among Wall Street analysts. How have TALS shares performed in 2023? Talaris Therapeutics' stock was trading at $1.02 at the beginning of 2023. Since then, TALS stock has increased by 1,759.8% and is now trading at $18.97. View the best growth stocks for 2023 here. How were Talaris Therapeutics' earnings last quarter? Talaris Therapeutics, Inc. (NASDAQ:TALS) posted its quarterly earnings data on Friday, November, 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.03. How often does Talaris Therapeutics pay dividends? What is the dividend yield for Talaris Therapeutics? Talaris Therapeutics announced a dividend on Thursday, October 19th. Stockholders of record on Monday, October 16th will be paid a dividend of $1.5118 per share on Friday, October 20th. The ex-dividend date of this dividend is Friday, October 20th. Read our dividend analysis for TALS. When did Talaris Therapeutics IPO? (TALS) raised $150 million in an initial public offering on Friday, May 7th 2021. The company issued 8,800,000 shares at $16.00-$18.00 per share. Morgan Stanley, SVB Leerink, Evercore ISI and Guggenheim Securities served as the underwriters for the IPO. Who are Talaris Therapeutics' major shareholders? Talaris Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include RA Capital Management L.P. (5.62%), Affinity Asset Advisors LLC (0.94%), Walleye Capital LLC (0.61%), Acuitas Investments LLC (0.45%), Marquette Asset Management LLC (0.09%) and Barclays PLC (0.04%). Insiders that own company stock include Francois Nader, Longitude Capital Partners Iii, Sandip Agarwala, Scott Requadt and Suzanne Ildstad. View institutional ownership trends. How do I buy shares of Talaris Therapeutics? Shares of TALS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:TALS) was last updated on 12/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Talaris Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.